Work

Genomic predictors of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): A real-world analysis from the PROMISE registry.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5066

Authors: Peter D. Zang, Nicholas Henderson, Deepak Kilari, Vadim S. Koshkin, Laura Graham, Alexandra Sokolova, Rohan Garje, Yousef Zakharia, Mehmet Asim Bilen, Pedro C. Barata, Clara Hwang, Rana R. McKay, Michael Thomas Schweizer, Andrew J. Armstrong, Zachery R. Reichert, Tanya B. Dorff

Institutions: City Of Hope National Medical Center, University of Michigan, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Colorado Cancer Center, Oregon Health & Science University, OHSU Knight Cancer Institute, University of Iowa Holden Comprehensive Cancer Center, Emory University, Winship Cancer Institute, University Hospitals Seidman Cancer Center, Case Western Reserve University, Henry Ford Health, Henry Ford Hospital, Moores Cancer Center, University of Washington, Fred Hutch Cancer Center, Duke University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162558852

Cites:

Cited by:

Related to: